Latest Headlines

Latest Headlines

Novo picks Clayton, NC, for its first U.S. API plant

Novo Nordisk has had filling, packaging and prefilled device manufacturing in Clayton, NC for years. Now the Danish drugmaker is betting its manufacturing future on the site. It will spend $1.2 billion on its first-ever U.S. API plant there and double the site's employment by adding 700 jobs.

Zoetis expands Nebraska facility even as its plots 10 plant closings

Animal health leader Zoetis has said that its massive cost-cutting plans will include whacking 10 unnamed manufacturing sites. But this week its manufacturing unit was taking solace in the expansion of one of its largest facilities.

Peptide maker to triple site with $18.8M project

A South Carolina-based peptide maker intends to spend nearly $19 million to triple the size of its plant and headquarters and has promised the state it will add 100 jobs in the next 5 years.

GSK expanding OTC plant that had been slated for sale

Several years ago, GlaxoSmithKline sold off a portfolio of consumer products in the U.S. The drugmaker had indicated a plant in Memphis, TN, was going to be sacrificed as part of that decision but GSK still has the plant and is even planning to spend some money making improvements to it.

Aurobindo lays out plans for 3 new plants

India's Aurobindo Pharma intends to beef up its manufacturing capacity over the next three years.

Mylan expands recalls from plants spanked in FDA warning letter

Just days after the FDA hammered Mylan sterile injectable plants in India in a warning letter, the drugmaker has said it is expanding a recall of injected cancer meds it manufactures there for Pfizer.

Indonesia's Kimia to build $71M plant to make herbal meds

Indonesia is working to bolster its domestic drugmaking and state-controlled drugmaker Kimia Farma has a list of projects in the works to help that happen. Its most recent is to build a manufacturing facility that will boost its production of herbal medicines.

Union posts email exchange with Merck CEO over plant dangers from job cuts

Merck & Co.'s plant in Pennsylvania has been impacted by the drugmaker's drastic job cuts in the last 5 years, losing hundreds of manufacturing jobs. Now, in an email exchange made public by one of the unions there, a labor official has lashed out at CEO Ken Frazier, saying workers are now forced to work 16-hours shifts, the fatigue from which puts themselves and others in danger.  

Hemispherx says plant upgrade will allow it to return its genital wart treatment to market

Hemispherx Biopharma has had a somewhat rocky relationship with both the FDA and the Street. But with a manufacturing upgrade complete and a distribution agreement in hand, it expects to return to the market its only approved product after a 7-year hiatus.

UPDATED: FDA castigates three Mylan sterile drug plants in warning letter

Mylan's recent recall of injected cancer drugs, was a hint that all was not well at some of the plants Mylan got two years ago in its $1.75 billion deal for Indian sterile injectables producer Agila Specialties. But just how deep those problems are came to light today when the FDA posted a warning letter for three of those Indian facilities, including one that was cited shortly before Mylan bought it.